Reporting on Adverse Clinical Events

T. Mcevoy
{"title":"Reporting on Adverse Clinical Events","authors":"T. Mcevoy","doi":"10.1177/0069477017709979","DOIUrl":null,"url":null,"abstract":"A 41-year-old male schizophrenic patient developed hypothermia after receiving 2 doses of zotepine (total dose: 150 mg) on hospitalization. Prior to admission, the patient had been receiving flupentixol (12 mg/day), which was stopped due to lack of therapeutic benefit. On admission, his body temperature was 36.4°C, but reduced to 34°C after receiving 2 doses of zotepine. Additional symptoms included sinus bradycardia (52 beats per minute), hypotension (97/66 mm Hg), and a Glasgow Coma Scale score of 3. Laboratory screenings and a computed tomography scan of the brain did not reveal a specific cause. Treatment included transfer to an intensive care unit and the discontinuation of zotepine. Over a 9-day period in the intensive care unit setting, the patient’s status and body temperature gradually recovered. A switch in medication to amisulpride (800 mg/day) and olanzapine (20 mg/day) on separate occasions was not helpful. However, the patient did respond to clozapine (200 mg/day). The remainder of his hospital stay was uneventful, and the patient was eventually discharged to the long-term care facility that he resided in prior to admission. The authors concluded that this patient experienced drug-induced hypothermia related to zotepine based on the temporal relationship between the administration of the drug and the appearance and resolution of symptoms. They encouraged clinicians to be aware of hypothermia associated with antipsychotics including zotepine and that body temperatures should be monitored in patients with schizophrenia. Zotepine [“Losizopilon,” “Lodopin,” “Setous,” “Zoleptil”] Chen TR et al (WC Ouyang, Department of Psychiatry, Changhua Christian Healthcare System and Changhua Christian Hospital, Changhua, Taiwan; e-mail: d88904@gmail.com) Zotepine-associated hypothermia in a schizophrenic inpatient. J Clin Psychopharmacol 37:367–368 (Jun) 2017","PeriodicalId":102871,"journal":{"name":"Clin-Alert®","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clin-Alert®","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/0069477017709979","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

A 41-year-old male schizophrenic patient developed hypothermia after receiving 2 doses of zotepine (total dose: 150 mg) on hospitalization. Prior to admission, the patient had been receiving flupentixol (12 mg/day), which was stopped due to lack of therapeutic benefit. On admission, his body temperature was 36.4°C, but reduced to 34°C after receiving 2 doses of zotepine. Additional symptoms included sinus bradycardia (52 beats per minute), hypotension (97/66 mm Hg), and a Glasgow Coma Scale score of 3. Laboratory screenings and a computed tomography scan of the brain did not reveal a specific cause. Treatment included transfer to an intensive care unit and the discontinuation of zotepine. Over a 9-day period in the intensive care unit setting, the patient’s status and body temperature gradually recovered. A switch in medication to amisulpride (800 mg/day) and olanzapine (20 mg/day) on separate occasions was not helpful. However, the patient did respond to clozapine (200 mg/day). The remainder of his hospital stay was uneventful, and the patient was eventually discharged to the long-term care facility that he resided in prior to admission. The authors concluded that this patient experienced drug-induced hypothermia related to zotepine based on the temporal relationship between the administration of the drug and the appearance and resolution of symptoms. They encouraged clinicians to be aware of hypothermia associated with antipsychotics including zotepine and that body temperatures should be monitored in patients with schizophrenia. Zotepine [“Losizopilon,” “Lodopin,” “Setous,” “Zoleptil”] Chen TR et al (WC Ouyang, Department of Psychiatry, Changhua Christian Healthcare System and Changhua Christian Hospital, Changhua, Taiwan; e-mail: d88904@gmail.com) Zotepine-associated hypothermia in a schizophrenic inpatient. J Clin Psychopharmacol 37:367–368 (Jun) 2017
不良临床事件报告
一名41岁男性精神分裂症患者住院后接受2剂唑替平(总剂量:150mg)后出现体温过低。入院前,患者一直在服用氟哌噻醇(12mg /天),由于缺乏治疗效果而停药。入院时,患者体温为36.4℃,经2剂左替平治疗后降至34℃。其他症状包括窦性心动过缓(每分钟52次),低血压(97/66 mm Hg),格拉斯哥昏迷评分为3分。实验室检查和脑部计算机断层扫描并没有显示出具体的原因。治疗包括转入重症监护病房和停用左替平。在重症监护病房的9天时间里,患者的状态和体温逐渐恢复。在不同的情况下,药物切换到氨硫pride(800毫克/天)和奥氮平(20毫克/天)没有帮助。然而,患者对氯氮平(200mg /天)有反应。他住院的其余时间平安无事,病人最终出院到他入院前住过的长期护理机构。基于给药与症状出现和消退之间的时间关系,作者得出结论,该患者经历了与佐替平相关的药物性低温。他们鼓励临床医生注意与抗精神病药物(包括唑替平)相关的体温过低,并且应该监测精神分裂症患者的体温。卓替平[“洛西匹仑”、“洛多平”、“塞妥斯”、“唑来替尔”]陈tr等(欧阳,台湾彰化基督教医疗系统、彰化基督教医院精神科;e-mail: d88904@gmail.com)精神分裂症住院患者与佐他平相关的低温症。中华精神病学杂志(英文版),2017
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信